List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8627460/publications.pdf

Version: 2024-02-01



CEDT II VAN 7VI

#	Article	IF	CITATIONS
1	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	13.7	1,381
2	Sixteen novel lineages of SARS-CoV-2 in South Africa. Nature Medicine, 2021, 27, 440-446.	15.2	326
3	HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts. Infectious Disorders - Drug Targets, 2011, 11, 167-174.	0.4	202
4	Adult antiretroviral therapy guidelines 2017. Southern African Journal of HIV Medicine, 2017, 18, 776.	0.3	155
5	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	6.0	144
6	Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings. Journal of Infectious Diseases, 2013, 207, S49-S56.	1.9	117
7	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 333-339.	0.9	101
8	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS ONE, 2015, 10, e0145772.	1.1	72
9	No evidence of HIV replication in children on antiretroviral therapy. Journal of Clinical Investigation, 2017, 127, 3827-3834.	3.9	66
10	Significantly Diminished Long-Term Specificity of the BED Capture Enzyme Immunoassay Among Patients With HIV-1 With Very Low CD4 Counts and Those on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 496-499.	0.9	64
11	Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen. Journal of Virology, 2012, 86, 6231-6237.	1.5	63
12	Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. PLoS ONE, 2013, 8, e67188.	1.1	59
13	Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. Journal of Infectious Diseases, 2015, 212, 39-43.	1.9	53
14	Pooling Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited Setting. Clinical Infectious Diseases, 2011, 52, 264-270.	2.9	52
15	HIV evolution and diversity in ART-treated patients. Retrovirology, 2018, 15, 14.	0.9	49
16	A genomics network established to respond rapidly to public health threats in South Africa. Lancet Microbe, The, 2020, 1, e229-e230.	3.4	46
17	Future technologies for monitoring HIV drug resistance and cure. Current Opinion in HIV and AIDS, 2017, 12, 182-189.	1.5	45
18	PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. Pediatric Infectious Disease Journal, 2009, 28, 1125-1127.	1.1	44

GERT U VAN ZYL

#	Article	IF	CITATIONS
19	HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-NaÃ <sup>-</sup> ve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High. PLoS ONE, 2011, 6, e23091.	1.1	43
20	Assessment of HIV transfusion transmission risk in South Africa: a 10â€year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes. Transfusion, 2019, 59, 267-276.	0.8	40
21	Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS ONE, 2016, 11, e0166305.	1.1	40
22	HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. Journal of Antimicrobial Chemotherapy, 2017, 72, 210-219.	1.3	37
23	Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure. Journal of Clinical Virology, 2015, 62, 48-53.	1.6	36
24	Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTIâ€based regimens in the western cape, South Africa. Journal of Medical Virology, 2011, 83, 1764-1769.	2.5	34
25	Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa. Journal of Clinical Virology, 2006, 37, 68-71.	1.6	31
26	Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. Journal of Medical Virology, 2008, 80, 942-946.	2.5	31
27	Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots. Journal of Clinical Virology, 2012, 53, 106-109.	1.6	31
28	Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. Aids, 2021, 35, 1423-1432.	1.0	31
29	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE, 2017, 12, e0181357.	1.1	31
30	Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. Journal of Infectious Diseases, 2013, 207, S70-S77.	1.9	30
31	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	2.7	28
32	Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor–Based Treatment: Results From the First National Survey in South Africa. Journal of Infectious Diseases, 2016, 214, 1826-1830.	1.9	25
33	Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge. Aids, 2018, 32, 629-634.	1.0	23
34	Lessons in diagnostic virology: expected and unexpected sources of error. Reviews in Medical Virology, 2019, 29, e2052.	3.9	23
35	Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life. Journal of Virology, 2020, 94,	1.5	22
36	Paper-based detection of HIV-1 drug resistance using isothermal amplification and an oligonucleotide ligation assay. Analytical Biochemistry, 2018, 544, 64-71.	1.1	21

#	Article	IF	CITATIONS
37	Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa. Pediatric Infectious Disease Journal, 2015, 34, 175-179.	1.1	20
38	<scp>HIV</scp> â€l <scp>DNA</scp> decay is faster in children who initiate <scp>ART</scp> shortly after birth than later. Journal of the International AIDS Society, 2019, 22, e25368.	1.2	20
39	Irreproducible positive results on the Cobas AmpliPrep/Cobas TaqMan HIV-1 Qual test are different qualitatively from confirmed positive results. Journal of Medical Virology, 2014, 86, 82-87.	2.5	19
40	Barriers to HIV remission research in low―and middleâ€income countries. Journal of the International AIDS Society, 2017, 20, 21521.	1.2	16
41	It is time to consider thirdâ€line options in antiretroviralâ€experienced paediatric patients?. Journal of the International AIDS Society, 2011, 14, 55-55.	1.2	15
42	Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa. AIDS Research and Human Retroviruses, 2016, 32, 80-84.	0.5	15
43	Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. Journal of Antimicrobial Chemotherapy, 2019, 74, 699-709.	1.3	13
44	Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2022, 38, 455-462.	0.5	13
45	Fatal SARSâ€CoVâ€2 Omicron variant in a young infant: Autopsy findings. Pediatric Pulmonology, 2022, 57, 1363-1365.	1.0	11
46	A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy. Journal of Clinical Virology, 2014, 60, 387-391.	1.6	9
47	The effect of interventions on the transmission and spread of HIV in South Africa: a phylodynamic analysis. Scientific Reports, 2019, 9, 2640.	1.6	9
48	A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 325-329.	0.9	9
49	SURVEILLANCE OF TRANSMITTED RESISTANCE TO ANTIRETROVIRAL DRUG CLASSES AMONG YOUNG CHILDREN IN THE WESTERN CAPE PROVINCE OF SOUTH AFRICA. Pediatric Infectious Disease Journal, 2010, 29, 370-371.	1.1	9
50	<scp>CD</scp> 4 countâ€based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone. Tropical Medicine and International Health, 2016, 21, 219-223.	1.0	8
51	Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy, 2022, 77, 483-491.	1.3	8
52	Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa. Database: the Journal of Biological Databases and Curation, 2014, 2014, bat082-bat082.	1.4	7
53	Pooled PCR testing of dried blood spots for infant HIV diagnosis is cost efficient and accurate. BMC Infectious Diseases, 2019, 19, 136.	1.3	7
54	Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children. MBio, 2021, 12, .	1.8	7

#	Article	IF	CITATIONS
55	NanoHIV: A Bioinformatics Pipeline for Producing Accurate, Near Full-Length HIV Proviral Genomes Sequenced Using the Oxford Nanopore Technology. Cells, 2021, 10, 2577.	1.8	7
56	Acute Extrapyramidal Dysfunction in Two HIV-infected Children. Journal of Tropical Pediatrics, 2011, 57, 227-231.	0.7	6
57	Moderate levels of preantiretroviral therapy drug resistance in a generalized epidemic. Aids, 2017, 31, 2387-2391.	1.0	6
58	High positive HIV serology results can still be false positive. IDCases, 2020, 21, e00849.	0.4	6
59	Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age. Aids, 2021, 35, 1247-1252.	1.0	6
60	HIV-1 Persistence in Children during Suppressive ART. Viruses, 2021, 13, 1134.	1.5	6
61	Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy. Southern African Journal of HIV Medicine, 2018, 19, 917.	0.3	6
62	Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. Southern African Journal of HIV Medicine, 2019, 20, 1008.	0.3	6
63	Extraction buffer contaminated bacterially as a cause of invalid HIV-1 viral load results on the NucliSens EasyQ® system. Journal of Virological Methods, 2008, 150, 80-81.	1.0	5
64	NucliSens EasyQ® HIV-1 V1.2 system: Detection of human plasma-derived background signal. Journal of Virological Methods, 2010, 165, 318-319.	1.0	5
65	Emerging antiretroviral drug resistance in sub-Saharan Africa. Aids, 2014, 28, 2643-2648.	1.0	5
66	Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. Clinical Infectious Diseases, 2021, 73, e643-e651.	2.9	5
67	Young age a predictor of weak reactivity in a rapid antibody test in infants infected with HIV. Journal of Medical Virology, 2010, 82, 1314-1317.	2.5	4
68	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatric Infectious Disease Journal, 2019, 38, 400-405.	1.1	4
69	Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring. African Journal of Laboratory Medicine, 2020, 9, 1035.	0.2	4
70	Antiretroviral Therapy in Children with Tuberculosis: Progress toward Defining the Issues. Journal of Infectious Diseases, 2010, 201, 1113-1114.	1.9	3
71	Late-Onset Hiv Encephalopathy In Children With Long-Standing Virologic Suppression Followed By Slow Spontaneous Recovery Despite no Change In Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2017, 36, e264-e267.	1.1	3
72	HIVIntact: a python-based tool for HIV-1 genome intactness inference. Retrovirology, 2021, 18, 16.	0.9	3

#	Article	IF	CITATIONS
73	Seroprevalence of Toxoplasma gondii infection among pregnant women in Windhoek, Namibia, in 2016. Southern African Journal of Infectious Diseases, 2020, 35, 25.	0.3	3
74	HIV drug resistance in a communityâ€randomized trial of universal testing and treatment: HPTN 071 (PopART). Journal of the International AIDS Society, 2022, 25, .	1.2	3
75	Another Milestone in Minimizing Risks to Mothers Exposed to Singleâ€Dose Nevirapine for Prevention of Vertical Transmission of HIVâ€1 to Infants: What Next?. Clinical Infectious Diseases, 2010, 50, 909-911.	2.9	2
76	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C. PLoS Computational Biology, 2021, 17, e1008363.	1.5	2
77	Routine use of fluoroscopic and realâ€time transthoracic echocardiographic guidance to ensure safety of right ventricular endomyocardial biopsy in a lowâ€volume center. Catheterization and Cardiovascular Interventions, 2022, 99, 1563-1571.	0.7	2
78	HIV drug resistance in various body compartments. Current Opinion in HIV and AIDS, 2022, 17, 205-212.	1.5	2
79	Is HIV-1C a risk factor for protease inhibitor failure?. Lancet HIV,the, 2016, 3, e149-e151.	2.1	1
80	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. Southern African Journal of Infectious Diseases, 2018, 33, 50-53.	0.3	1
81	PhyloPi: An affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility. PLoS ONE, 2019, 14, e0213241.	1.1	1
82	HIV false positive screening serology due to sample contamination reduced by a dedicated sample and platform in a high prevalence environment. PLoS ONE, 2021, 16, e0245189.	1.1	1
83	Appropriate clinical use of darunavir 800 mg. Southern African Journal of HIV Medicine, 2018, 19, 918.	0.3	1
84	The Namibian poliomyelitis outbreak and its consequences for South Africa. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2006, 48, 3-6.	0.2	0
85	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. Southern African Journal of Infectious Diseases, 2018, 33, 50-53.	0.3	0
86	Rapid emergence of resistance to antiretroviral treatment after undisclosed prior exposure: A case report. Southern African Journal of HIV Medicine, 2019, 20, 965.	0.3	0
87	Intrapartum human immunodeficiency virus transmission rate in a central hospital in the Western Cape province after universal antiretroviral therapy roll-out. Southern African Journal of Infectious Diseases, 2020, 35, 192.	0.3	0
88	Delays in HIV-1 infant polymerase chain reaction testing may leave children without confirmed diagnoses in the Western Cape province, South Africa. African Journal of Laboratory Medicine, 2022, 11, .	0.2	0